Back to results
US 9,789,233 B2Granted
Stents having bioabsorbable layers
AssigneeMicell Technologies, Inc.
InventorsJames B. McClain, Douglas Taylor
Life of this patent
Estimating the term…
Abstract
Provided herein is a device comprising: a. stent; b. a plurality of layers on said stent framework to form said device; wherein at least one of said layers comprises a bioabsorbable polymer and at least one of said layers comprises one or more active agents; wherein at least part of the active agent is in crystalline form.
Claims22
A device comprising:
- a. a stent consisting essentially of layers of polymer and layers of pharmaceutical agent;
- b. a plurality of layers deposited directly on said stent;
- wherein at least one of said polymer layers comprises a bioabsorbable polymer and at least one of said pharmaceutical agent layers comprises a pharmaceutical agent selected from rapamycin, a prodrug, a derivative, an analog, a hydrate, an ester, and a salt thereof in intimate contact with said bioabsorbable polymer, wherein at least a portion of the pharmaceutical agent is in crystalline form, wherein said device provides an in vitro elution profile in which 5% to 25% of the pharmaceutical agent is eluted one day after the device is contacted with elution media.
A device comprising:
- a. a stent consisting essentially of layers of polymer and layers of pharmaceutical agent;
- b. a plurality of layers deposited directly on said stent, wherein a first layer comprises a first bioabsorbable polymer, a second layer comprises a layer of a first pharmaceutical agent, a third layer comprises a second bioabsorbable polymer, a fourth layer comprises a layer of said first pharmaceutical agent, and a fifth layer comprises a third bioabsorbable polymer,
- wherein the first pharmaceutical agent is selected from rapamycin, a prodrug, a derivative, an analog, a hydrate, an ester, and a salt thereof, and wherein said device has a first pharmaceutical agent content of about 1 μg/mm to about 15 μg/mm, and
- wherein at least a portion of the first pharmaceutical agent is in crystalline form.
1 more element
A device comprising:
- a. a stent consisting essentially of layers of polymer and layers of pharmaceutical agent;
- b. a plurality of layers on said stent;
- wherein at least one of said polymer layers comprises a solvent free bioabsorbable polymer and at least one of said pharmaceutical agent layers comprises a pharmaceutical agent selected from rapamycin, a prodrug, a derivative, an analog, a hydrate, an ester, and a salt thereof in intimate contact with said solvent free bioabsorbable polymer, wherein at least a portion of the pharmaceutical agent is in crystalline form,
- wherein said device provides an in vitro elution profile in which
- 5% to 25% of the pharmaceutical agent is eluted one day after the device is contacted with elution media;
- 15% to 45% of the pharmaceutical agent is eluted 7 days after the device is contacted with elution media;
- 25% to 60% of the pharmaceutical agent is eluted 14 days after the device is contacted with elution media;
- 35% to 70% of the pharmaceutical agent is eluted 21 days after the device is contacted with elution media;
- and
- 40% to 100% of the pharmaceutical agent is eluted 28 days after the device is contacted with elution media.
7 more elements
Dependencies are inferred from the claim text.